Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of tulisokibart in Crohn’s disease or ulcerative colitis
2024-513533-20-00Phase 3Authorised
- Sponsor
- Merck & Co.
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, open-label, single-arm trial of tulisokibart in Crohn's disease and autoimmune colitis, sponsored by Merck & Co. Primary endpoints: Percentage of participants with ≥1 adverse event and Percentage of participants discontinuing from study therapy due to adverse event. Planned start Jan 2025; status: authorised.
02
Drugs
tulisokibart
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on 2024-513533-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513533-20-00.